Featured Slider

With 2022 named European Year of Youth by the European Commission, the EAN President Elect takes a look at all the initiatives EAN offers to support young neurologists

EAN Programme Committee Chair, Tony Marson, on abstract submission, registration and the preliminary programme for EAN 2022.

Our research paper of the month is a multicentre, randomised and double-blind phase 2 study with a futility design, exploring the efficacy and the safety of guanabenz in patients with probable or definite amyotrophic lateral sclerosis (ALS).

Our authors of the month conducted a systematic review of SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography (PMCT) and medical record review.

EAN President, Claudio Bassetti gives some deep insights into the EAN's recent advocacy activity and plans for the future.

Our research paper of the month is an open-label, single-arm, phase II futility trial exploring the safety and the effect of treatment with the antimalarial drug hydroxychloroquine on disability worsening in patients with primary progressive multiple sclerosis.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.

EAN President, Claudio Bassetti provides a general update and insights into the EAN’s current activities and priorities.

Our research paper of the month is a retrospective cohort study, aiming to investigate the association between field position, professional career length and playing era and increased risk of neurodegenerative disease among male former professional soccer players.

The aim of this study was to describe neurological and psychiatric complications of infection with SARS CoV 2 in children and adolescents and determine the prevalence of such manifestations in hospitalised patients under 18 years-old.

EAN Secretary General, Elena Moro, provides an update on membership-related issues, including a range of new benefits for EAN members.

For October 2021, we have selected: Spelman T. el al Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

For October 2021, we have selected: Lopez Bernal J. et al, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant: test-negative case–control study.

EAN Scientific Committee Chair, Thomas Berger, gives early notice of the upcoming elections for Scientific Panel Management Groups and an update on recent scientific activities.

For September 2021, we have selected: Ramsden CE et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial